P21‐activated kinase 1 regulates resistance to BRAF inhibition in human cancer cells

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Molecular Carcinogenesis

• Publication date

  2017-05-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1002/mc.22611PMID 28052407PMCID PMC5392142
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• c‐Met‐mediated reactivation of PI3K/AKT signaling contributes to insensitivity of BRAF(V600E) mutant thyroid cancer to BRAF inhibition

  2016cited by this paper
• Proteomic analysis of Rac1 signaling regulation by guanine nucleotide exchange factors

  2016cited by this paper
• Registered Report: COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

  2016cited by this paper
• BRAF associated autophagy exploitation: BRAF and autophagy inhibitors synergise to efficiently overcome resistance of BRAF mutant colorectal cancer cells

  2016cited by this paper
• Targeting of the MAPK and AKT pathways in conjunctival melanoma shows potential synergy

  2016cited by this paper
• BRAF inhibitor resistance enhances vulnerability to arginine deprivation in melanoma

  2016cited by this paper
• Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.

  2015cited by this paper
• Combinatorial drug screening and molecular profiling reveal diverse mechanisms of intrinsic and adaptive resistance to BRAF inhibition in V600E BRAF mutant melanomas

  2015cited by this paper
• Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer

  2015cited by this paper
• C-Met-mediated reactivation of PI3K AKT signaling contributes to insensitivity of BRAF(V600E) mutant thyroid cancer to BRAF inhibition

  2015cited by this paper
• Inhibitors of p21-activated kinases (PAKs).

  2015cited by this paper
• The c-Jun/RHOB/AKT pathway confers resistance of BRAF-mutant melanoma cells to MAPK inhibitors

  2015cited by this paper
• A melanoma subtype with intrinsic resistance to BRAF inhibition identified by receptor tyrosine kinases gene-driven classification

  2015cited by this paper
• Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade

  2015cited by this paper
• BRAF inhibitor resistance mediated by the AKT pathway in an oncogenic BRAF mouse melanoma model

  2015cited by this paper
• Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma

  2014cited by this paper
• The RAC1 P29S hotspot mutation in melanoma confers resistance to pharmacological inhibition of RAF.

  2014influential reference
• Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study.

  2014cited by this paper
• BRAF activates and physically interacts with PAK to regulate cell motility.

  2014cited by this paper
• Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma

  2014influential reference
• BRAF-mutant hematopoietic malignancies

  2014cited by this paper
• Differential effects of the oncogenic BRAF inhibitor PLX4032 (vemurafenib) and its progenitor PLX4720 on ABCB1 function.

  2014cited by this paper
• Activities of multiple cancer-related pathways are associated with BRAF mutation and predict the resistance to BRAF/MEK inhibitors in melanoma cells

  2014cited by this paper
• Rac1-dependent recruitment of PAK2 to G2 phase centrosomes and their roles in the regulation of mitotic entry

  2014cited by this paper
• BRAF inhibitors in cancer therapy.

  2014cited by this paper
• The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.

  2014cited by this paper
• P21-activated kinase 1 (PAK1) as a therapeutic target in BRAF wild-type melanoma.

  2013cited by this paper
• Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.

  2013cited by this paper
• FOXO1 regulates expression of a microRNA cluster on X chromosome

  2013cited by this paper
• Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation.

  2012cited by this paper
• p21-Activated kinase 1 is required for efficient tumor formation and progression in a Ras-mediated skin cancer model.

  2012cited by this paper
• Vemurafenib: the first drug approved for BRAF-mutant cancer

  2012cited by this paper
• The response to PAK1 inhibitor IPA3 distinguishes between cancer cells with mutations in BRAF and Ras oncogenes

  2012cited by this paper
• Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial.

  2012cited by this paper
• A landscape of driver mutations in melanoma.

  2012cited by this paper
• Combinatorial treatments that overcome PDGFRβ-driven resistance of melanoma cells to V600EB-RAF inhibition.

  2011cited by this paper
• Long-Distance Effects of Insertional Mutagenesis

  2011cited by this paper
• Improved survival with vemurafenib in melanoma with BRAF V600E mutation.

  2011cited by this paper
• PP2A-B56α Controls Oncogene-Induced Senescence in Normal and Tumor Human Melanocytic Cells

  2011cited by this paper
• Akt3-mediated resistance to apoptosis in B-RAF-targeted melanoma cells.

  2010cited by this paper
• Drug combination studies and their synergy quantification using the Chou-Talalay method.

  2010cited by this paper
• Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K.

  2010cited by this paper
• Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

  2010cited by this paper
• PAK1 as a therapeutic target

  2010influential reference
• COT/MAP3K8 drives resistance to RAF inhibition through MAP kinase pathway reactivation

  2010cited by this paper
• The role of PAK-1 in activation of MAP kinase cascade and oncogenic transformation by Akt

  2009cited by this paper
• Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.

  2009cited by this paper
• An isoform-selective, small-molecule inhibitor targets the autoregulatory mechanism of p21-activated kinase.

  2008cited by this paper
• A Natural Human Retrovirus Efficiently Complements Vectors Based on Murine Leukemia Virus

  2008cited by this paper
• Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

  2008influential reference
• Biological Characterization of ARRY-142886 (AZD6244), a Potent, Highly Selective Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor

  2007cited by this paper
• Role of Group A p21-activated Kinases in Activation of Extracellular-regulated Kinase by Growth Factors*

  2005cited by this paper
• Detection of B-RAF and N-RAS mutations in human melanoma.

  2005cited by this paper
• Analysis of BRAF Mutation in Primary and Metastatic Melanoma

  2005cited by this paper
• B-Raf and Raf-1 Are Regulated by Distinct Autoregulatory Mechanisms*

  2005cited by this paper
• PAK Is Essential for RAS-Induced Upregulation of Cyclin D1 During the G1 to S Transition

  2004cited by this paper
• p21-activated Kinase 1 Phosphorylates and Regulates 14-3-3 Binding to GEF-H1, a Microtubule-localized Rho Exchange Factor*

  2004cited by this paper
• Detection of mutations in the mitogen-activated protein kinase pathway in human melanoma.

  2003cited by this paper
• Akt Phosphorylation of Serine 21 on Pak1 Modulates Nck Binding and Cell Migration

  2003cited by this paper
• Mutations of the BRAF gene in human cancer

  2002cited by this paper
• Phosphatidylinositol 3-kinase regulates Raf1 through Pak phosphorylation of serine 338.

  2000cited by this paper
• The Akt Proto-oncogene Links Ras to Pak and Cell Survival Signals*

  2000influential reference
• The regulation and activities of the multifunctional serine/threonine kinase Akt/PKB.

  1999cited by this paper
• Signals from the Ras, Rac, and Rho GTPases Converge on the Pak Protein Kinase in Rat-1 Fibroblasts

  1999cited by this paper
• Cloning and Characterization of GEF-H1, a Microtubule-associated Guanine Nucleotide Exchange Factor for Rac and Rho GTPases*

  1998influential reference
• PAK kinases are directly coupled to the PIX family of nucleotide exchange factors.

  1998cited by this paper
• Actions of Rho family small G proteins and p21-activated protein kinases on mitogen-activated protein kinase family members

  1996cited by this paper
• Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line.

  1990cited by this paper
• Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors.

  1984cited by this paper

• Inhibition of the RAC/PAK Signaling Axis Enhances the Potency of MAPK Cascade Inhibitors Against Uveal Melanoma

  2025influential citation
• A novel PAK1/TCF1 regulatory axis promotes non-small cell lung cancer progression

  2025cites this paper
• Inhibitors of De Novo Guanylate Biosynthesis Enhance the Potency of MAPK Cascade Inhibitors Against Colorectal Cancer

  2025influential citation
• A critical role of FAK signaling in Rac1-driven melanoma cell resistance to MAPK pathway inhibition

  2025cites this paper
• Exploring resistance to immune checkpoint inhibitors and targeted therapies in melanoma

  2024cites this paper
• PAK1 and Therapy Resistance in Melanoma

  2023cites this paper
• miR-224-5p acts as a tumour suppressor and reverses the resistance to BRAF inhibitor in melanoma through directly targeting PAK4 to block the MAPK pathway.

  2023cites this paper
• Hyperactivation of p21-Activated Kinases in Human Cancer and Therapeutic Sensitivity

  2023cites this paper
• The Effect of Honey Bee Venom on CD14 Protein Expression as Monocyte Marker in D-Alpha-Tocopheryl Succinate (Vitamin E)-Treated HL-60 Cells

  2022influential citation
• Immune Checkpoint Inhibitors and RAS–ERK Pathway-Targeted Drugs as Combined Therapy for the Treatment of Melanoma

  2022cites this paper
• PAK6 promotes homologous-recombination to enhance chemoresistance to oxaliplatin through ATR/CHK1 signaling in gastric cancer

  2022cites this paper
• Cancer drug discovery as a low rank tensor completion problem

  2021cites this paper
• p21-Activated kinases as promising therapeutic targets in hematological malignancies

  2021cites this paper
• Proteotoxic Stress as an Exploitable Vulnerability in Cells with Hyperactive AKT

  2021cites this paper
• p21-activated kinases in thyroid cancer.

  2020cites this paper
• 10H‐3,6‐Diazaphenothiazines triggered the mitochondrial‐dependent and cell death receptor‐dependent apoptosis pathways and further increased the chemosensitivity of MCF‐7 breast cancer cells via inhibition of AKT1 pathways

  2020cites this paper
• P21-Activated Kinase 1: Emerging biological functions and potential therapeutic targets in Cancer

  2020cites this paper
• Coordinated dysregulation of cancer progression by the HER family and p21-activated kinases

  2020cites this paper
• Blockage of PAK1 alleviates the proliferation and invasion of NSCLC cells via inhibiting ERK and AKT signaling activity

  2020cites this paper
• Mechanisms of Acquired BRAF Inhibitor Resistance in Melanoma: A Systematic Review

  2020cites this paper
• p21-activated kinase 6 controls mitosis and hepatocellular carcinoma progression by regulating Eg5.

  2020cites this paper
• IODVA1, a guanidinobenzimidazole derivative, targets Rac activity and Ras-driven cancer models

  2020cites this paper
• The role of polo‐like kinase 3 in the response of BRAF‐mutant cells to targeted anticancer therapies

  2019influential citation
• Whole‐exome sequencing reveals novel genetic variants associated with diverse phenotypes of melanoma cells

  2019cites this paper
• The role of PAK1 in the sensitivity of kidney epithelial cells to ischemia-like conditions

  2019cites this paper
• PAK Kinase Inhibition Has Therapeutic Activity in Novel Preclinical Models of Adult T-Cell Leukemia/Lymphoma

  2019cites this paper
• MAPK- and AKT-activated thyroid cancers are sensitive to group I PAK inhibition.

  2019cites this paper
• R

  2019cites this paper
• P21 activated kinase signaling in cancer.

  2019cites this paper
• In vitro antitumor activity of progesterone in human adrenocortical carcinoma

  2018cites this paper
• Protein-Protein Interactions: Emerging Oncotargets in the RAS-ERK Pathway.

  2018cites this paper
• Melanoma-associated mutants within the serine-rich domain of PAK5 direct kinase activity to mitogenic pathways

  2018cites this paper
• Reversal of Resistance in Targeted Therapy of Metastatic Melanoma: Lessons Learned from Vemurafenib (BRAFV600E-Specific Inhibitor)

  2018cites this paper
• Author Correction: PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas

  2018cites this paper
• Type II RAF inhibitor causes superior ERK pathway suppression compared to type I RAF inhibitor in cells expressing different BRAF mutant types recurrently found in lung cancer

  2018cites this paper
• Relevance of small GTPase Rac1 pathway in drug and radio-resistance mechanisms: Opportunities in cancer therapeutics.

  2018cites this paper
• The RhoJ-BAD signaling network: An Achilles’ heel for BRAF mutant melanomas

  2017cites this paper